Disclaimer
These statements are related, among others, to the intent, belief or current expectations of the customer base, estimates regarding future growth in the different business lines and the global business, market share, financial results and other aspects of the activities and situation relating to the Company. Such forward-looking statements are not guarantees of future performance and involve risks and uncertainties, and actual results may differ materially from those expressed in or implied by these forward-looking statements as a result of various factors, many of which are beyond the ability of DiaSorin S.p.A. to control or estimate precisely. The Company does not undertake to update or otherwise revise any forecasts or objectives presented herein, except in compliance with the disclosure obligations applicable to companies whose shares are listed on a stock exchange. Luigi De Angelis, the Officer Responsible for the preparation of corporate financial reports of DiaSorin S.p.A., in accordance with the second subsection of art. 154-bis, part IV, title III, second paragraph, section V-bis, of Legislative Decree February 24, 1998, no. 58, declares that, to the best of his knowledge, the financial information included in the present document corresponds to book of accounts and book-keeping entries of the Company.Â
2015-2017 PLAN:
MARKET AND PRODUCTS
IVD Market: Immunodiagnostic and Molecular Diagnostic
In Vitro Diagnostic (IVD) Market Value: ~ 造 45 billion POINT OF CARE MICROBIOLOGY HAEMATOLOGY
7%
OTHER MOLECULAR DIAGNOSTIC
9% 12%
6% 6%
CLINICAL CHEMISTRY
18% 21% 21% SELF-MONITORING BLOOD GLUCOSE
IMMUNODIAGNOSTIC
IVD Market Immunodiagnostic Market
Molecular Diagnostic Market
Value: ~ 造 8.1 billion
Value: ~ 造 5.4 billion
ONCOLOGY AND ENDOCRINOLOGY
OTHER
26% DRUG MONITORING ALLERGY
18%
26% 25%
HEPATITIS AND RETROVIRUSES
3% 6%
AUTOIMMUNITY
15%
7%
GI STOOL TESTING
5%
7%
BONE&MINERAL
15%
CARDIAC MARKERS
Bone & Mineral
2015
INFECTIOUS DISEASE
2016
Molecular Diagnostic Pipeline 2017
Infectious Diseases
Bordetella G* Bordetella A* PCT II* HCV II
*Already available on the market
Qualitative Onco-Haematology
Campylobacter
H. Pylori IgG Endocrinology
AREA
2015
2016
PML-RAR 1-3
AML-ETO 1
PML-RAR 2
CBF D-E
2017
Sclerostin FGF-23
GI Stool Testing
INFECTIOUS DISEASES
13%
Immunodiagnostic Pipeline AREA
60%
ONCOLOGY
CBF A 6 to 8 Tests
6 to 8 Tests
Quantitative Onco-Haematology
BCR-ABL P210
BCR-ABL P190 + ABL
BCR-ABL ABL
PML-RAR 1 + ABL PML-RAR 2 + ABL PML-RAR 3 + ABL